This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence–Powered Scribes
Lisa S. Rotenstein, MD, MBA, MSc, et al.. JAMA, 2026.
DOI: doi:10.1001/jama.2026.2253
-
Predicting gastric cancer response to anti-PD-1 first-line treatment based on multi-modal data: A multi-center study
2026.
-
Clinical characterization of immune checkpoint inhibitor-induced myocarditis and the triple M overlap syndrome
Hassan Mohammed Abushukair, et al.. 2026.
Weekly News Brief: April 27–May 1, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of April 27–May 1, 2026.
This week’s brief covers a large evaluation of AI-powered scribes’ clinical efficiency benefits, an AI model for predicting fatality from immune checkpoint inhibitor–related myocarditis, and a deep learning model for predicting immunotherapy response in gastric cancer.
To learn more about the AI ambient scribes analysis, read "AI Scribes Reduce Documentation Burden but Deliver Modest Gains in Efficiency, Multisite Study Finds," or see the source report in JAMA.
For more information on the model for myocarditis fatality prediction, read "Model Aims to Predict Immunotherapy-Related Myocarditis Fatalities," or see the abstract.
To learn more about the model for immunotherapy response in gastric cancer, read "Multimodal Deep Learning for First-Line Immunotherapy Response in Gastric Cancer," or see the abstract.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.